AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

3

- 1. (Original) A recombinant plasmid vector pSNAV1/HO-l, comprising a heme oxygenase-1 (HO-1) gene.
- 2. (Currently Amended) An adeno-associated viral (AAV) vector cell strain, wherein the eell strain is obtained by transforming a cell with comprising the recombinant plasmid vector of claim 1.
- 3. (Currently Amended) The AAV vector cell strain of claim 2, wherein the cell strain is obtained by transforming is a BHK-21 cell.
- 4. (Original) The AAV vector cell strain of claim 3, wherein the cell strain is BHK/HO-1.
- 5. (Original) A recombinant virus produced from the recombinant plasmid vector of claim 1.
 - 6. (Original) A recombinant virus produced from the AAV vector cell strain of claim 2.
 - 7. (Original) A recombinant virus produced from the AAV vector cell strain of claim 4.
- 8. (Original) The recombinant virus of claim 7, wherein the recombinant virus is rAAV/HO-l.
- 9. (Currently Amended) A process for the production of the <u>a</u> recombinant adenoassociated virus rAAV/HO-1, the process comprising transforming a host cell <u>in vitro</u> with the <u>a</u>

4

Application No. 10/750,620 Amendment dated April 25, 2006 Reply to Office Action of January 4, 2006

recombinant plasmid vector pSNAVI/HO-1 having an HO-1 gene, and transfecting the host cell <u>in</u> <u>vitro</u> with recombinant virus HSVI-rc.

- 10. (Original) The process of claim 9, wherein the host cell is a BHK cell.
- 11. (Currently Amended) A method of mediating providing for increasing expression of the an HO-1 gene in an organ of an animal, wherein the method comprises administering directly to the organ by in situ perfusion an effective amount of a recombinant adeno-associated viral vector, wherein the recombinant viral vector comprises the HO-1 gene and the effective amount of the recombinant viral vector is at least the amount required to increase carboxyhemoglobin in the peripheral blood of the animal transplanted with the perfused organ compared to carboxyhemoglobin in the peripheral blood of an animal not transplanted with the perfused organ.
- 12. (Withdrawn) A method of preventing post-transplant chronic transplant rejection, wherein the method comprises administering an effective amount of the recombinant virus of claim 5.
- 13. (Withdrawn) A method of preventing post-transplant chronic transplant rejection, the method comprising administering an effective amount of the recombinant virus of claim 6.
- 14. (Withdrawn) A method of preventing post-transplant chronic allograft rejection, the method comprising expressing the HO-1 gene in grafts.
- 15. (Withdrawn) The method of claim 14, wherein expression of the HO-1 gene in grafts is mediated by a recombinant adeno-associated virus.
- 16. (Withdrawn) The method of claim 14, further comprising constructing a plasmid bearing the HO-1 gene, and producing a recombinant adeno-associated virus bearing the HO-1 gene.

5

Application No. 10/750,620 Amendment dated April 25, 2006 Reply to Office Action of January 4, 2006

17. (Withdrawn) The method of claim 14, wherein expressing the HO-1 gene in grafts can be carried out by methods such as gene delivery method, protein delivery method and/or using substance for the induction of stable HO-1 expression.

18. (New) The method of claim 11, wherein the organ is a heart.